New Delhi: Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its Covid-19 vaccine ZyCoV-D.

The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement. ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, it added.

Source:
https://www.thehansindia.com/news/national/zydus-cadila-gets-dcgi-nod-to-initiate-phase-3-trials-665258

Similar articles:

Leave a Reply

Your email address will not be published. Required fields are marked *